RxDoctor Payments Data

Lori Lebow, MD

Ophthalmology · Gainesville, GANPI 1376652883

Payments from drug & device makers

$9,754in general payments, 2019–2025

Across 238 payments — averaging $40.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$2K
  • Alcon$2K
  • AbbVie$903
  • Eyevance Pharmaceuticals LLC$603
  • Lensar, Inc.$593
  • Tarsus Pharmaceuticals, Inc.$385
  • plus $3K from 19 others

What the payments were for

  • Travel & lodging$120%
  • Food & beverage$9,706100%
  • Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,754 in reported general payments places this provider in the 80th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$391,177
Medicare patients
1,261
Services billed
3,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost276$135,070
XdemvyLotilaner44$81,791
RestasisCyclosporine45$54,965
RocklatanNetarsudil Mesylat/Latanoprost46$23,684
XiidraLifitegrast26$23,051
Cyclosporine24$20,267
SimbrinzaBrinzolamide/Brimonidine Tart45$12,194
TyrvayaVarenicline Tartrate17$12,037
RhopressaNetarsudil Mesylate17$11,637
CombiganBrimonidine Tartrate/Timolol23$9,866
MieboPerfluorohexyloctane/Pf11$9,777
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol35$9,088
Alphagan PBrimonidine Tartrate31$8,311
VyzultaLatanoprostene Bunod17$6,962
Brimonidine Tartrate51$6,791

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$903$208,212375 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$385$81,79144 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$326$39,79054 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$35$35,32063 claims
AlconSimbrinza$2,170$12,19445 claims
Oyster Point Pharma, Inc.Tyrvaya$264$12,03717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →